December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
Pilot Study of Intravitreal Injection of Triamcinolone Acetonide in Exudative Age-Related Macular Degeneration
Author Affiliations & Notes
  • SJ Moon
    Ophthalmology Baylor College of Medicine Houston TX
  • WF Mieler
    Ophthalmology Baylor College of Medicine Houston TX
  • ER Holz
    Ophthalmology Baylor College of Medicine Houston TX
  • Footnotes
    Commercial Relationships   S.J. Moon, None; W.F. Mieler, None; E.R. Holz, None.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 1220. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      SJ Moon, WF Mieler, ER Holz; Pilot Study of Intravitreal Injection of Triamcinolone Acetonide in Exudative Age-Related Macular Degeneration . Invest. Ophthalmol. Vis. Sci. 2002;43(13):1220.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To investigate the safety and efficacy of intravitreal injection of triamcinolone acetonide (Kenalog) in exudative age-related macular degeneration (AMD) patients with predominantly occult (<50% classic) subfoveal choroidal neovascularization (CNV). Methods: A randomized prospective pilot clinical trial involving a single injection of triamcinolone acetonide (4 mg/0.1 ml) into the vitreous cavity of treatment eyes (6 patients) versus a single injection of saline solution (0.1 ml) into the vitreous cavity of control eyes (2 patients) was performed. Complete ocular examination with LogMAR visual acuity assessment was performed at baseline, 1 day, 1, 3, and 6 months following enrollment. Fluorescein angiography was performed at baseline, 3, and 6 months. Results: Overall, the treatment eyes had more LogMAR visual acuity improvement (-0.23 to -0.28) than the control eyes (-0.05 to -0.1) throughout the study. Three treatment eyes demonstrated significant visual improvement at 1 day (-0.43), 1 month (-0.3), 3 months (-0.47), and 6 months (-0.33). The other treatment eyes and the control eyes remained relatively stable with their visual acuity change staying within -0.17. Fluorescein angiography showed stability or improvement with reduction in leakage in the treatment eyes at 3 and 6 months. The treatment eyes that responded well appeared to have occult CNV with minimal or no classic component. One treatment eye experienced a transient increase in intraocular pressure which necessitated medical intervention. There was no significant cataract progression in the treatment eyes. Conclusion: Intravitreal triamcinolone appears to be relatively well tolerated and may provide immediate visual improvement in some patients with exudative AMD with predominantly occult CNV. The effect may persist for at least up to 6 months. This observation may result from a combination of the anti-inflammatory and anti-angiogenic properties of triamcinolone. Further study is ongoing.

Keywords: 308 age-related macular degeneration • 357 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×